Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS

NCT04901416 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

AML, Adult Recurrent
MDS

Interventions

BIOLOGICAL: DVX201

Sponsor

Coeptis Therapeutics

Collaborators

[object Object]